evipedia.ai
← Back

Butea monosperma for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: Butea frondosa, Palash, Palasha, Dhak, Flame of the Forest, Bastard Teak, Parrot Tree, Bengal Kino, Kimshuka, Tesu

Motivation

Butea monosperma is a flowering tree native to the Indian subcontinent, known locally as palash and in English as the flame of the forest for its vivid orange blossoms. Its flowers, bark, seeds, and gum have long been used in traditional Indian medicine. Modern interest rests on its chemistry: the flowers are among the richest natural sources of butein, an orange plant pigment, while the bark carries a separate family of molecules that act on bone-building cells.

The tree appears in classical Indian medical writing, and preparations of its different parts remain in everyday use across South Asia. Laboratory and animal research over the past two decades has followed a narrower thread than the traditional record — whether the bark molecules can slow the bone loss that follows menopause, and whether butein changes how long simple laboratory organisms live and how well they withstand stress.

This review examines what the evidence shows for Butea monosperma: which of its compounds are active and by what route, what the research supports and where it runs out, what harms the different parts of the plant carry, and how the preparations sold today differ from one another.

Benefits - Risks - Protocol - Conclusion

This section lists high-level, directly relevant sources that orient a reader to Butea monosperma and its principal constituents before the detailed evidence sections.

Note on priority sources: no content on Butea monosperma, its common names, or its constituent butein could be found on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com or lifespan.io. Both a web search and a direct on-site search were run for each. The plant is essentially absent from the English-language longevity commentary these platforms produce, so the five items above are drawn from the primary and narrative-review literature instead.

Grokipedia

  • Butea monosperma

    A long-form encyclopedic entry covering taxonomy, phytochemistry, ecology and traditional uses, useful for the botanical and cultural background that pharmacology papers routinely omit.

Examine

  • Butea monosperma

    Examine’s independent read is short but pointed: it identifies the bark isoflavones and medicarpin as the most promising bone-active molecules and states plainly that no human dosing evidence exists.

ConsumerLab

No ConsumerLab article, product review or test report for Butea monosperma exists. A direct site search returned only two unrelated recall notices covering adulterated sexual-enhancement products.

Systematic Reviews

No systematic reviews or meta-analyses for Butea monosperma were found on PubMed as of 17 August 2026.

The intervention involves a clear trade-off between its claimed benefits and its principal risk, suppression of male reproductive function, and neither side of that trade-off is represented: the literature contains no systematic review or meta-analysis of any claimed effect, and none of the reproductive or chronic toxicity data either.

Mechanism of Action

Butea monosperma has no single active compound; its parts carry distinct molecule families.

The flowers are dominated by chalcones — butein and its glycosides butrin, isobutrin and isocoreopsin. These block IκB kinase (the enzyme that releases NF-κB, or nuclear factor kappa B, a master switch that turns on inflammatory genes), lowering output of TNF-α (tumour necrosis factor alpha, a signalling protein that drives inflammation), IL-6 (interleukin-6) and IL-8 (interleukin-8). Butein is separately a sirtuin-activating compound: it stimulates SIRT1 (an enzyme that uses NAD+, an energy-carrying helper molecule, to switch on stress-resistance genes), and in nematodes its effects require DAF-16 (the worm counterpart of the FOXO stress-response transcription factors) plus BEC-1 (an autophagy protein; autophagy is the cell’s recycling process).

The stem bark carries a different class: the methoxyisoflavones cladrin, cajanin and isoformononetin, and the pterocarpan medicarpin. These push osteoblasts (bone-forming cells) toward differentiation and mineralisation, and the standardised fraction does so without stimulating uterine tissue, so the route is largely non-estrogenic. Flower extract additionally suppresses cartilage-degrading enzymes by inhibiting mTOR (mechanistic target of rapamycin, a nutrient-sensing growth switch), raising autophagy.

The seeds contain palasonin, a close relative of cantharidin, underlying both the traditional deworming action and the seeds’ toxicity. The gum is mostly tannins and acts as a surface astringent.

A competing reading holds butein acts non-specifically: its catechol ring is reactive toward proteins, so effects credited to named targets may reflect a general stress response. The fluorescence assays that first reported sirtuin activation have been contested as artefacts.

Historical Context & Evolution

The plant’s original documented uses are Ayurvedic and bear little relation to how it is studied today. Classical Indian medical texts list palasha for expelling intestinal worms (the seeds), for diarrhoea and dysentery (the astringent gum), for liver complaints and inflammatory skin conditions (the flowers), and as a general tonic (the bark). The tree was the principal host for the lac insect and the source of the orange festival dye, which kept it economically visible.

Its formal pharmaceutical career began with the gum. “Bengal kino” was an official astringent in nineteenth-century British and Indian pharmacopoeias, largely as a cheaper substitute for Malabar kino. Chemical work followed: palasonin was isolated from the seeds and characterised for both anthelmintic (worm-expelling) activity and toxicity by Raj and Kurup in 1968, and Wagner and colleagues identified isobutrin and butrin as the flowers’ liver-protecting principles in 1986.

Two later findings redirected attention. In 2003 butein appeared alongside resveratrol and quercetin in the first screen for sirtuin-activating small molecules, pulling the plant into aging biology. From 2008 the CSIR–Central Drug Research Institute in Lucknow — which has pursued these molecules as drug candidates and so holds an institutional stake in a positive result — isolated the bark methoxyisoflavones and reported osteoprotective effects.

The sirtuin claim did not settle. The fluorogenic assay behind the 2003 screen was later argued to produce activation artefacts, and defenders replied with substrate-dependent binding data. Neither position has been tested in a mammal for butein, so the question remains genuinely open.

Expected Benefits

High 🟩 🟩 🟩

No benefit of Butea monosperma reaches this evidence level. No adequately powered randomised controlled trial of the plant, any of its extracts, or any of its isolated compounds has been published in humans.

Medium 🟩 🟩

No benefit reaches this evidence level either. There are no cohort studies, no repeated small human trials, and no dose-response human data for any endpoint.

Low 🟩

Preservation of Bone Mass After Estrogen Loss

A standardised acetone-soluble bark fraction rich in cladrin, isoformononetin and medicarpin prevented bone loss in ovariectomized rats and stimulated new bone formation. The effect was largely non-estrogenic, which is the mechanistically interesting part. All data are rodent; the sponsoring institute holds a development interest in these molecules.

Magnitude: The standardised fraction at 100 mg/kg/day matched or exceeded the whole extract at 1,000 mg/kg/day for trabecular bone mineral density, microarchitecture, mineral apposition rate and bone formation rate. No human bone-density figure exists.

Protection of the Liver Against Chemical Injury

An ethyl acetate bark fraction normalised liver injury markers in thioacetamide-poisoned rats and restored fibrosis markers toward baseline. The flower glycosides isobutrin and butrin were identified as liver-protecting principles decades earlier, so two independent lines converge. No human liver endpoint has been measured.

Magnitude: The bark fraction at 50–200 mg/kg normalised serum bilirubin, aminotransferases, albumin and alkaline phosphatase, with superoxide scavenging at a half-maximal concentration of 89 µg/mL. No human liver-enzyme change has been reported.

Reduced Blood Glucose and Improved Blood Lipids

An ethanol bark extract lowered blood glucose in streptozotocin-diabetic rats and improved the lipid profile in the same model. Leaf extracts inhibit the carbohydrate-digesting enzymes α-glucosidase and α-amylase, giving a plausible route. Findings are rodent-only and not uniform across extracts.

Magnitude: Ethanol bark extract at 500 mg/kg/day for 60 days cut blood glucose by 41% and raised plasma insulin by 38% in diabetic rats, with partial restoration of lipids; no human blood-glucose outcome figure exists.

Suppression of Inflammatory Signalling in Joint and Skin Tissue

Butrin, isobutrin and butein selectively inhibit NF-κB in activated human mast cells, cutting inflammatory cytokine output. A standardised flower extract suppressed the same signals in human osteoarthritis cartilage cells. The skin work was done by a cosmetics manufacturer’s research arm, a commercial interest worth naming.

Magnitude: In human skin keratinocytes the flower extract cut interleukin-1β, interleukin-6 and interleukin-8 secretion by 32%, 33% and 18% respectively; joint effects were measured as gene and protein expression only.

Reduced Symptoms of Urinary Stone Disease

An alkaline ash preparation of the plant combined with a herbal decoction outperformed placebo in a small open-label trial in patients with urinary stones. This is the only placebo-controlled human evidence for any Butea monosperma preparation. The design was open-label and the treatment was a two-component combination.

Magnitude: In 39 participants over two months the treated group reported greater relief of pain and urinary frequency and more complete symptom remission than placebo; the report gives no effect size or stone-clearance figure.

Clearance of Intestinal Worms

Seed preparations are the plant’s oldest documented medical use, and methanol seed extract shows significant anthelmintic activity in vitro. Seed powder also cut faecal egg counts in naturally infected sheep. The active principle, palasonin, is the same molecule responsible for the seeds’ toxicity.

Magnitude: Seed powder at 3 g/kg reduced eggs per gram of sheep faeces by 78.4% at day 10, against 99.1% for levamisole; the effect holds only at seed doses that also carry toxicity, and no human clearance-rate figure exists.

Relief of Diarrhoea and Dysentery

Ethanolic bark extract inhibited castor-oil diarrhoea and prostaglandin-driven fluid secretion in rats while slowing gut transit, and the tannin-rich gum acts as a surface astringent. This is the plant’s classical use for diarrhoea and dysentery. Rodent-only, single laboratory, no human endpoint.

Magnitude: Direction is toward less castor-oil-induced diarrhoea, reduced prostaglandin-driven fluid secretion into the gut and slower transit, holding at the oral bark-extract doses tested; the report gives no percentage figure and no human stool-frequency outcome exists.

Reduced Weight Gain and Increased Energy Expenditure

A butein-enriched flower extract reduced weight gain and raised energy expenditure in diet-induced obese mice by inducing UCP1 (uncoupling protein 1, the protein that lets fat cells burn energy as heat). Butein was confirmed as the active ingredient. Rodent-only, single laboratory, short duration.

Magnitude: Mice given 70 mg/kg/day gained less weight and showed higher oxygen consumption, rectal temperature and glucose tolerance than high-fat-diet controls; no human weight-change figure exists.

Accelerated Healing of Skin Wounds

Topical alcoholic bark extract sped dermal wound closure in rats, raising collagen synthesis, tensile strength and cell proliferation in the healing tissue. A later computational docking study proposed which constituents bind wound-repair proteins but tested none of them. Topical use only, and untested in people.

Magnitude: Direction is toward faster regrowth of skin across the wound, greater wound contraction and higher tensile strength, holding from day 4 of treatment onward; the literature reports no percentage closure figure and no human healing-time outcome.

Protection of the Kidney Against Drug-Induced Injury

Ethanolic leaf extract reversed gentamicin-induced kidney injury in rats, normalising creatinine, urea and blood urea nitrogen. The proposed route is the extract’s flavonoid and phenolic antioxidant content. Rodent-only, single laboratory, and against a specific drug toxin rather than chronic kidney disease.

Magnitude: Direction is toward normalised serum creatinine, urea and blood urea nitrogen against a gentamicin-poisoned control, holding at the oral doses tested; the report gives no percentage change and no human kidney outcome exists.

Relief of Nerve Pain

Ethanolic leaf extract reduced pain behaviour in rats with chemotherapy-induced nerve damage, matching pregabalin, a standard nerve-pain drug. Proposed routes are antioxidant action and calcium channel inactivation. All data are rodent, from one laboratory, in a drug-induced rather than spontaneous neuropathy.

Magnitude: Direction is toward reduced heat and pressure sensitivity and less cold allodynia (pain from a normally painless cold stimulus), dose-dependent over 14 days; the report gives no percentage figure and no human pain score exists.

Suppression of Seizure Activity

A triterpene fraction of the flowers blocked seizures in several rodent models, and an earlier paper from the same laboratory reported the same for a flower fraction alongside raised brain calming neurotransmitters. The two reports share authors, so they are not independent replication, and all data are rodent.

Magnitude: The triterpene fraction protected half of the animals against electroshock seizures at 34.2 mg/kg, rising to 51.5 mg/kg after seven days of repeated dosing; no human seizure outcome exists.

Protection Against Genotoxic and Oxidative DNA Damage

Leaf extract reduced chromosome damage from cyclophosphamide in mice, restoring lipid peroxidation and glutathione toward normal, and flower powder limited arsenic-induced mitochondrial DNA damage in rats. Two independent laboratories converge; both used a chemical insult rather than ordinary ageing.

Magnitude: Direction is toward less chromosome damage in blood and bone marrow against a cyclophosphamide-treated control, and toward higher mitochondrial DNA copy number with fewer deletions against arsenic; the reports give no percentage figure and no human DNA-damage outcome exists.

Growth Inhibition of Bacteria and Fungi

Seed oil killed bacteria and fungi in laboratory culture, and medicarpin isolated from the stem bark outperformed a standard fungicide against a test mould. A flower flavone glycoside was active against several fungal species. All data are laboratory-dish work against test organisms, with no infection model in any animal.

Magnitude: Direction is toward growth inhibition of bacteria and fungi in culture, with medicarpin reported as more potent than the reference fungicide against Cladosporium cladosporioides; the reports give no inhibitory concentration and no human infection outcome exists.

Resistance to Stress and Modest Memory Support

Aqueous leaf extract protected rats against stress-induced stomach lesions, while both the aqueous and the alcoholic extract normalised white cell counts and improved learning and recall. The same study found no anti-anxiety effect. A second laboratory reversed drug-induced amnesia in rats. Rodent-only, with no human data.

Magnitude: Both extracts at 300 mg/kg for seven days improved acquisition and retention of a learned task in rats; the report gives no effect size, and no human stress or memory outcome exists.

Support of Erectile Function and Sexual Behaviour

Bark extract improved sexual behaviour in male rats, and a second laboratory relaxed penile smooth muscle and raised sperm output by inhibiting Rho-kinase 2 (an enzyme that keeps that muscle contracted). The material is bark, not the flower extract behind the reproductive harm below. Rodent-only.

Magnitude: Bark extract at 400 mg/kg/day for 28 days shortened mount, intromission and ejaculation latencies and raised their frequencies in rats, and methanol bark extract relaxed penile smooth muscle by about 22%; no human sexual-function outcome exists.

Antitumour Activity

Flower extract kills tumour cells in culture and slowed liver tumour development in one transgenic mouse model. A second laboratory curbed chemically induced mammary tumours in rats. The basis is cell-culture work plus two controlled animal models, with no study in spontaneous disease.

Magnitude: Direction is toward slower liver tumour development, with normalised liver enzymes and lower tumour blood-vessel signalling, holding at the oral doses tested in the transgenic model; the report gives no tumour-incidence figure and no human cancer outcome exists.

Speculative 🟨

Extension of Lifespan and Stress Resistance ⚠️ Conflicted

Butein extended mean lifespan in nematodes by about 10%, requiring DAF-16 and autophagy, with reduced fertility as a trade-off. Evidence is invertebrate and mechanistic; the underlying sirtuin-activation claim is itself contested.

Benefit-Modifying Factors

  • Catechol-clearing enzyme variants: Butein carries a catechol ring, the same chemical feature COMT (catechol-O-methyltransferase, the enzyme that inactivates catechol compounds) acts on. Fast-COMT variants would plausibly shorten exposure, though no pharmacogenetic study of this plant exists.

  • Conjugation-enzyme variants: UGT1A1 and SULT1A1 (enzymes that attach sugar or sulfate groups to flavonoids for excretion) carry common activity-altering variants. Low-activity carriers would retain higher free chalcone levels; this is inferred from flavonoid pharmacology, not measured here.

  • Baseline biomarker levels: Every measured benefit appears in models with a pathological baseline — chemically injured liver, streptozotocin-induced diabetes, estrogen-depleted bone. Individuals already within optimal ranges for liver enzymes, fasting glucose and bone turnover have the least headroom for benefit.

  • Sex-based differences: The bone evidence comes entirely from ovariectomized female rats, so the benefit case is strongest for postmenopausal women. For men the same preparations carry a documented reproductive downside with no offsetting bone data.

  • Pre-existing health conditions: Bone benefit was demonstrated only against established estrogen-deficient bone loss, and glucose benefit only in chemically induced diabetes. Existing liver disease may increase exposure by slowing conjugation, but this has not been measured.

  • Age-related considerations: Postmenopausal women and older men are the group with the most plausible benefit, since bone loss and glucose dysregulation both rise with age. Conjugation capacity and renal clearance decline past 70, raising exposure at any given dose.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk of Butea monosperma reaches this evidence level. No human safety trial, pharmacovigilance database entry or post-marketing surveillance programme covers this plant.

Medium 🟥 🟥

No risk reaches this evidence level. There is no published human case series, poisoning registry entry or observational safety study for any preparation of this plant.

Low 🟥

Suppression of Male Reproductive Function

Methanolic flower extract reduced fertility, sperm count, motility and viability in male rats with disrupted testicular architecture. This is the plant’s best-replicated harm, consistent with its documented folk use as a male antifertility agent and with reduced spermatogenesis seen in chronic seed toxicity work. It reversed fully after withdrawal.

Magnitude: Male rats given 500 mg/kg/day for 180 days showed a 40% fall in fertility rate with significant drops in sperm count, motility and viability; normal function returned within 45 days of stopping.

Systemic Toxicity from Seed Preparations

Seed powder produced measurable organ and blood toxicity in a 90-day rat study, affecting kidney, spleen, gut, testis and red cell parameters. The likely driver is palasonin, chemically close to cantharidin, a class known for mucosal blistering and renal tubular injury. Seeds are the plant part to avoid.

Magnitude: Rats given 800 mg/kg/day for 90 days showed significant falls in haemoglobin, red cell count, haematocrit, total protein and albumin, rises in triglycerides and very-low-density lipoprotein, and kidney tubular haemorrhage; the report gives no percentage change for any parameter and no human toxicity figure exists.

Additive Blood-Glucose Lowering

Bark and leaf extracts lower blood glucose in diabetic rodents and inhibit carbohydrate-digesting enzymes. Combined with glucose-lowering medication or fasting, this creates a plausible route to hypoglycaemia (blood sugar falling below the safe range). No combination study exists, so the concern is mechanistic rather than observed.

Magnitude: Not quantified in available studies. No study has combined the plant with a glucose-lowering drug in humans or animals, so the size of any additive fall in blood glucose is unknown.

Slowed Bowel Transit and Reduced Iron Absorption

Bark extract reduced gastrointestinal motility and fluid secretion in rats, which is the basis of the traditional antidiarrhoeal use and equally the basis for constipation at higher intakes. The gum is heavily tannin-based; dietary tannins reliably bind non-heme iron and reduce its absorption.

Magnitude: Direction is toward slowed transit, reduced castor-oil-induced diarrhoea and reduced prostaglandin-driven fluid secretion, holding at antidiarrhoeal doses upward; the literature reports no human tolerability or iron-absorption figure for this plant.

Estrogen-Receptor Activity and Pregnancy Risk ⚠️ Conflicted

The evidence here is directly conflicted. The whole bark extract was mildly uterus-stimulating in adult ovariectomized rats and both estrogenic and antiestrogenic in immature rats, while the standardised fraction from the same plant was neither. Whether a given product carries hormonal activity therefore depends entirely on how it was prepared.

Magnitude: The whole extract at 1,000 mg/kg/day mildly stimulated uterine tissue, the standardised fraction at 100 mg/kg/day was not; no human hormone-level figure exists.

Suppression of Thyroid Hormone Output

Stigmasterol from the bark lowered circulating thyroid hormones in mice alongside its glucose-lowering effect, so the two actions travel together. This matters most for anyone already on thyroid replacement or with borderline thyroid function. Single laboratory, one isolated constituent, no human data.

Magnitude: Stigmasterol at 2.6 mg/kg/day for 20 days reduced serum triiodothyronine and thyroxine in mice; the same study found the highest dose tested, 5.2 mg/kg, turned pro-oxidative. No human thyroid-hormone figure exists.

Sedation and Central Nervous System Depression

A flower fraction acted as a central nervous system depressant in rodents, failing to shorten barbiturate-induced sleep, and an earlier paper from the same laboratory found the fraction anxiogenic (anxiety-provoking) and generally depressant, with raised brain calming neurotransmitters. No human sedation report exists.

Magnitude: Direction is toward sedation and reduced spontaneous activity, holding at the anticonvulsant doses of roughly 34–52 mg/kg in rodents; the literature reports no human drowsiness rate and no dose at which the effect appears in people.

Speculative 🟨

Allergic and Contact Skin Reactions

Chalcones are chemically reactive toward proteins, the property that lets small molecules act as contact allergens. No sensitisation data exist for this plant; the basis is mechanistic plus isolated reports of skin reactions.

Unpredictable Interference with Cancer Immunotherapy

Butein suppresses PD-L1 (a protein tumours use to evade immune attack), cutting it in lung cancer cells and mice. No study has combined it with a checkpoint-blocking drug, so this is mechanistic conjecture only.

Risk-Modifying Factors

  • Catechol and conjugation enzyme variants: Low-activity COMT, UGT1A1 or SULT1A1 variants would slow clearance of the chalcones and raise systemic exposure at a given dose. This is inferred from flavonoid pharmacology; no genotype-stratified data exist for this plant.

  • Baseline biomarker levels: Low baseline haemoglobin, ferritin or serum albumin marks the individuals most exposed to the haematological and protein changes seen with chronic seed dosing. Baseline liver enzymes and creatinine identify reduced capacity to clear and tolerate the extract.

  • Sex-based differences: The reproductive harm is documented only in males, where it is the dominant concern. In females the dominant concern is hormonal instead, since whole bark extract showed uterine estrogenic activity that the purified fraction did not.

  • Pre-existing health conditions: Chronic kidney disease, existing liver disease, and hormone-sensitive cancers each intersect directly with a documented effect — renal tubular injury from seeds, slowed clearance, and uterine stimulation from whole extracts.

  • Age-related considerations: Declining renal and hepatic clearance past 70 raises exposure at any fixed dose. Older adults are also more often on glucose-lowering or anticoagulant medication, which is where the plausible interactions sit.

Key Interactions & Contraindications

  • Glucose-lowering medication (metformin, glimepiride, glipizide, insulin): Caution, with additive risk of hypoglycaemia given the plant’s demonstrated glucose-lowering action in animals. Mitigation: more frequent capillary glucose checks for two weeks, with any reduction taken from the plant dose rather than the medication.

  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin): Caution, with a theoretical increase in bleeding risk, since chalcones inhibit platelet aggregation in laboratory assays. Mitigation: avoidance within two weeks of surgery, and international normalised ratio checks for anyone on warfarin.

  • Narrow-therapeutic-index drugs cleared by the liver (tacrolimus, ciclosporin, warfarin): Caution, with unpredictable changes in drug levels, because flavonoids and chalcones inhibit drug-metabolising enzymes in vitro. Mitigation: drug level measurement before starting and two weeks after, or complete avoidance.

  • Thyroid replacement (levothyroxine, liothyronine, desiccated thyroid): Monitor, with a possible fall in thyroid hormone levels, since a bark constituent lowered circulating thyroid hormones in mice. Mitigation: thyroid-stimulating hormone and free thyroxine at eight weeks, with dosing separated by four hours.

  • Hormone therapy and estrogen-receptor modulators (estradiol, raloxifene, tamoxifen): Caution, since whole bark extract showed both estrogenic and antiestrogenic behaviour in animals, which could add to or oppose the drug. Mitigation: standardised non-estrogenic fractions only, or avoidance.

  • Over-the-counter anti-inflammatories (ibuprofen, naproxen, aspirin): Caution, with additive gastrointestinal mucosal irritation, which matters most for seed-containing preparations given palasonin’s cantharidin-like chemistry. Mitigation: dosing with food, four-hour separation, and complete exclusion of seed preparations.

  • Sedatives and central nervous system depressants (benzodiazepines, zolpidem, opioids, alcohol): Caution, with additive sedation, since a flower fraction was a central nervous system depressant in rodents that did not shorten barbiturate-induced sleep. Mitigation: no combined dosing, and no driving until the individual response is known.

  • Over-the-counter iron and mineral supplements (ferrous sulfate, zinc, calcium): Monitor, with reduced mineral absorption caused by the tannin-rich gum binding non-heme iron. Mitigation: at least two hours between the plant and the mineral supplement.

  • Blood-glucose-lowering supplements (berberine, chromium picolinate, bitter melon, alpha-lipoic acid): Caution, with additive hypoglycaemia. These are the supplements most likely to compound the plant’s own effect. Mitigation: one glucose-lowering agent introduced at a time, with fasting glucose tracked.

  • Phytoestrogen supplements (soy isoflavones, red clover, kudzu): Caution, with additive estrogen-receptor activity when whole bark extracts are used. Mitigation: no stacking, and preference for preparations standardised to the non-estrogenic methoxyisoflavone fraction.

  • Liver-loading supplements (high-dose green tea catechins, kava, comfrey): Caution, with additive hepatic burden despite the plant’s own hepatoprotective signal, since human liver tolerance is unmeasured. Mitigation: no stacking, with liver enzymes at eight weeks.

  • Other longevity interventions (fisetin, quercetin, resveratrol) and senolytic protocols (agents that clear worn-out cells): Monitor, since these share sirtuin and stress-response targets with butein and the combined effect is unstudied. Mitigation: separate trials of each, at least four weeks apart, so effects remain attributable.

Populations who should avoid Butea monosperma:

  • Pregnancy, at any stage, and lactation — the plant has documented folk use as an abortifacient (an agent that ends a pregnancy) and shows uterine estrogenic activity in animals

  • Men actively attempting conception, or with a baseline sperm concentration below 15 million/mL

  • Hormone-sensitive cancers — estrogen-receptor-positive breast, endometrial and ovarian cancer, whether active or in remission

  • Chronic kidney disease stage 3 or worse, meaning an estimated glomerular filtration rate below 60 mL/min/1.73 m², given documented renal tubular injury in animals

  • Decompensated liver disease, Child-Pugh Class B or C

  • Anyone within two weeks of scheduled surgery, and anyone on a narrow-therapeutic-index drug without level monitoring

  • Children and adolescents under 18, in whom no dosing or safety data of any kind exist

Risk Mitigation Strategies

  • Flower or bark only, never seed: Every documented organ toxicity comes from seed preparations at 800 mg/kg/day, driven by palasonin. Flower or bark material removes the most serious identified harm at no cost to the bone or metabolic evidence.

  • Species verification before use: A label reading Butea monosperma rather than Butea superba matters, since the latter is a different species sold for sexual enhancement and repeatedly recalled for undeclared prescription drugs. This prevents inadvertent exposure to hidden pharmaceuticals.

  • Quarter starting dose with titration over four weeks: Protocols begin near 750 mg of flower or bark powder daily, doubling every two weeks toward 3 g. Slow escalation surfaces gastrointestinal irritation and hypoglycaemia before they become significant.

  • Liver panel at baseline, week 8 and week 24: This covers alanine aminotransferase, aspartate aminotransferase, albumin and bilirubin. Since human liver tolerance is unmeasured, it converts an unknown into a monitored one and catches the protein changes seen in animals.

  • Semen analysis for men of reproductive age: A baseline reading, repeated at 12 weeks where use continues, directly monitors the plant’s best-replicated harm. Rodent data show reproductive parameters recover within 45 days of stopping.

  • Two-hour separation from iron and mineral supplements: Tannin-rich preparations, especially the gum, bind non-heme iron. Timing separation prevents the iron-deficiency risk without requiring either supplement to be dropped.

  • Continuous use capped at 12 weeks, then reassessed: No human safety data extend beyond two months of continuous use. A defined stopping point prevents indefinite exposure accumulating the haematological and reproductive changes seen with chronic animal dosing.

Therapeutic Protocol

  • No validated human dose: No dose-finding study exists in humans for any preparation. Everything below is either traditional practice or extrapolated from animal work, and describes the current state of practice rather than validated dosing.

  • Classical Ayurvedic preparations: Practitioners at Ayurvedic teaching hospitals use flower powder at roughly 3–6 g daily, bark decoction at 40 mL twice daily, and the alkaline ash at 500 mg three times daily after meals.

  • Standardised-fraction approach: The alternative, developed at the CSIR–Central Drug Research Institute in Lucknow by Maurya and Chattopadhyay’s groups, uses an acetone-soluble bark fraction standardised to methoxyisoflavones at roughly one-tenth the whole-extract dose. Neither approach has been compared in humans.

  • Isolated-compound approach: A third route treats butein or medicarpin as single research compounds rather than using plant material. This remains preclinical, has no commercial supply chain, and cannot currently be pursued outside a laboratory.

  • Best time of day: With food, and in the morning when combined with any glucose-lowering agent, so that a hypoglycaemic dip falls during waking hours. Food also reduces the gastrointestinal irritation that tannin-rich preparations cause on an empty stomach.

  • Half-life: No human pharmacokinetic study of this plant or butein has been published. Rodent work indicates rapid absorption followed by extensive conjugation in gut and liver, implying a short plasma residence measured in hours rather than days.

  • Single versus split dosing: Split dosing is the consistent traditional practice — two to three divided doses — matching the rapid conjugation seen in animals. A single daily dose gives a brief peak with little exposure thereafter.

  • Genetic polymorphisms: COMT, UGT1A1 and SULT1A1 variants plausibly alter chalcone exposure, and slow-conjugator genotypes argue for the lower end of any range. No pharmacogenetic study of this plant exists, so this remains inference from flavonoid pharmacology.

  • Sex-based differences: For postmenopausal women the bone rationale applies and dosing follows the bark-fraction evidence. For men of reproductive age the reproductive harm dominates, arguing for lower doses, shorter courses, and semen monitoring.

  • Age-related considerations: Protocols place adults over 70 at the lower end of any range, since conjugation capacity and renal clearance both decline and no geriatric dosing data exist. Bone-directed use is also most relevant in this group.

  • Baseline biomarker levels: Fasting glucose, liver enzymes, haemoglobin and bone turnover markers before starting determine both the plausible benefit and the tolerance margin. Individuals already in optimal ranges have little measurable headroom.

  • Pre-existing health conditions: Reduced kidney or liver function argues for the lowest dose or avoidance, since clearance is the limiting factor. Diabetes on medication argues for morning dosing and closer glucose monitoring during titration.

Discontinuation & Cycling

  • Short-term rather than lifelong: No human data support continuous use beyond the two-month trial duration, and animal toxicity accumulates with duration rather than dose alone. Time-limited courses fit the evidence far better than indefinite daily intake.

  • Withdrawal effects: None documented in any species. Neither the rodent chronic toxicity work nor the human trial reported rebound, dependence or discontinuation symptoms, and no constituent has a known receptor-dependence mechanism.

  • Tapering protocol: Not required by the available evidence. Abrupt cessation was used in every animal study and in the human trial without reported difficulty, so tapering serves no identified purpose here.

  • Cycling for efficacy: No tolerance or efficacy loss has been demonstrated, so cycling is not needed for that reason. Cycling remains reasonable for safety, since a break lets reproductive and haematological parameters recover.

  • Practical cycle structure: Twelve weeks on followed by at least four weeks off matches the 45-day recovery of reproductive parameters seen in rats after withdrawal. Each break is the natural point for reassessing liver enzymes and, in men, semen parameters.

Sourcing and Quality

  • Species verification is the first check: The relevant label distinction is Butea monosperma against Butea superba. The two are separate species with separate uses, and Butea superba products have been recalled for containing undeclared prescription erectile dysfunction drugs.

  • Declared plant part: Flower, bark, seed, gum and leaf differ chemically and in safety. A product labelled only “Butea” or “Palash powder” without a named part cannot be assessed, and seed content is the specific thing to exclude.

  • Standardisation markers: Anti-inflammatory intent points to standardisation against butein, butrin or isobutrin; bone intent points to methoxyisoflavone content — cladrin, isoformononetin, medicarpin. Most retail powders declare neither and are simply milled plant material.

  • Heavy metal and pesticide testing: Ayurvedic herbal products have a documented history of lead, mercury and arsenic contamination, particularly ash-based preparations. A batch certificate of analysis showing heavy metals, pesticide residues and microbial limits is the minimum useful documentation.

  • Third-party verification: No ConsumerLab, USP or NSF verified Butea monosperma product exists. In its absence, the established Ayurvedic manufacturers that publish per-batch certificates carry more documentation than the rest — Banyan Botanicals, Himalaya Wellness and Dabur are the most transparent widely available options.

  • Form and freshness: Dried flower and bark powders lose chalcone content with light and heat exposure. Opaque packaging, a stated harvest or manufacture date, and suppliers with rapid turnover all favour retained potency over bulk sacks of unknown age.

Practical Considerations

  • Time to effect: No human time-course data exist. The single human trial ran two months before assessing symptoms; rodent bone effects required 12 weeks. A realistic assessment window is therefore 8–12 weeks, not days.

  • Common pitfall — using seed preparations: Seeds carry the plant’s documented organ toxicity while offering only the deworming benefit. Traditional anthelmintic use was short-course and supervised; buying seed powder for general daily use inverts the risk-benefit entirely.

  • Common pitfall — species confusion: Butea superba is a different plant sold for a different purpose and repeatedly adulterated. Searching by common name rather than binomial makes this mistake easy and is the single most consequential sourcing error.

  • Common pitfall — assuming isolated-compound data transfers: Most encouraging findings involve purified fractions or single molecules at defined doses. Crude milled powder contains these at unknown and variable concentration, so the published effects cannot be assumed to carry over.

  • Regulatory status: In the United States it is an unapproved dietary supplement. In India it is a classical drug regulated by the Ministry of Ayush, a body that also promotes the sector it regulates and so has an institutional interest in favourable assessments.

  • Cost and accessibility: Raw powder is inexpensive — typically under $20 for 200 g — but standardised extracts are effectively unavailable outside research settings. Established payers have no incentive to fund studies of an unpatentable plant competing with prescription bone drugs.

Interaction with Foundational Habits

  • Sleep: The direction is direct and plausibly sedating rather than none: a triterpene fraction of the flowers acted as a central nervous system depressant in rodents and did not shorten pentobarbitone-induced sleep. No human sleep measure exists for any preparation, which makes evening dosing the more cautious placement and daytime drowsiness the signal of interest.

  • Nutrition: The interaction is direct and blunting for mineral status: tannins in the gum and bark bind non-heme iron and reduce its absorption. At least two hours away from iron-rich meals and iron supplements limits that loss. Chalcone absorption is modestly improved when taken with dietary fat, so a fat-containing meal is the better pairing.

  • Exercise: The plausible direction is blunting, by the same route proposed for high-dose antioxidant vitamins — damping the transient reactive oxygen species signal that drives training adaptation. This has never been tested for this plant. As a precaution, dosing at the opposite end of the day from training avoids overlap with sessions.

  • Stress management: The interaction is potentiating in mechanism and unmeasured in effect. Butein engages the same stress-response pathways — FOXO and Nrf2 (the cell’s antioxidant-defence switch) — that fasting, heat exposure and exercise recruit, so overlap is expected. No cortisol, heart rate variability or perceived-stress data exist for this plant in any species.

Monitoring Protocol & Defining Success

Because no human safety dataset exists for this plant, baseline testing carries more weight here than for a well-characterised intervention. A baseline panel therefore covers liver function, kidney function, a full blood count with iron status, fasting glucose, and — where bone is the reason for use — bone turnover markers and vitamin D. For men of reproductive age the panel extends to a semen analysis, since reproductive suppression is the plant’s best-replicated harm. These baselines identify the groups the evidence excludes, and make any later change interpretable.

Ongoing monitoring follows a defined cadence: the liver panel and blood count at 8 weeks, fasting glucose at 4 and 12 weeks where any glucose-lowering agent is in use, and semen analysis at 12 weeks in men continuing past one cycle. Bone turnover markers and bone density are reassessed at 6 and 12 months respectively.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT 10–20 U/L (men), 8–18 U/L (women) Detects liver cell injury ALT is alanine aminotransferase, an enzyme released when liver cells are damaged. Conventional labs flag only above 40–55 U/L, which misses early change. Fasting sample preferred
AST 10–25 U/L Confirms and contextualises an ALT rise AST is aspartate aminotransferase, a second liver enzyme also present in muscle. Conventional labs flag only above about 40 U/L. Best paired with ALT; a high AST with normal ALT usually points to muscle, not liver
Albumin 4.2–5.0 g/dL Tracks liver synthetic capacity Chronic seed dosing lowered total protein and albumin in rats. Conventional range starts at 3.5 g/dL, which is well below optimal. Best paired with total protein
Total bilirubin 0.4–1.0 mg/dL Detects bile handling problems Rodent work showed bilirubin changes in both directions depending on model. Conventional labs accept 0.1–1.2 mg/dL, so a value below 0.4 passes unremarked. Fasting sample; uninterpretable in known Gilbert’s syndrome (a common harmless inherited variant that raises bilirubin on its own)
Fasting glucose 75–86 mg/dL Catches additive glucose lowering Requires a 10–12 hour fast. Conventional labs accept 70–99 mg/dL. Most useful when any glucose-lowering drug or supplement is in use; pair with HbA1c (glycated haemoglobin, which reflects average glucose over about three months) for a longer view
HbA1c 4.8–5.3% Shows glucose control over months Reflects average glucose over roughly the preceding three months. Conventional labs call anything below 5.7% normal. Unreliable if haemoglobin is falling, which this plant may cause — best read alongside the blood count
Haemoglobin and haematocrit 13.5–15.0 g/dL (men), 12.5–14.0 g/dL (women) Detects the anaemia seen in chronic animal dosing Haemoglobin, red cell count and haematocrit all fell in the 90-day rat study. Conventional labs accept 13.5–17.5 g/dL (men) and 12.0–15.5 g/dL (women), so an early fall stays inside range. Best drawn with ferritin, since tannins also impair iron absorption
Ferritin 50–125 ng/mL (men), 40–100 ng/mL (women) Tracks iron stores against tannin binding Conventional labs accept 15–300 ng/mL. Ferritin rises with inflammation, so it is interpretable only alongside a marker of inflammation
eGFR Above 90 mL/min/1.73 m² Screens the organ showing tubular injury in animals eGFR is estimated glomerular filtration rate, a calculated measure of kidney filtering capacity. Conventional labs flag only below 60 mL/min/1.73 m². Best drawn with creatinine and cystatin C; heavy protein intake or intense exercise beforehand distorts the result
CTX Lower half of the age-and-sex reference range Measures the rate of bone breakdown CTX is C-terminal telopeptide, a fragment released as bone is resorbed. Highly diurnal and food-sensitive — a fasting sample before 9 a.m. is required. Best paired with P1NP (procollagen type 1 N-terminal propeptide, released when bone is built)
P1NP 30–60 µg/L in postmenopausal women Measures the rate of new bone formation Conventional postmenopausal reference ranges run roughly 15–80 µg/L, which is far wider. The paired reading with CTX shows whether turnover is balanced. Less diurnal than CTX
25-hydroxyvitamin D 40–60 ng/mL Sets the precondition for any bone benefit Bone-directed use makes little sense below 30 ng/mL. Conventional sufficiency starts at 20 ng/mL. No fasting required; test at the same season year to year
TSH and free T4 TSH 0.5–2.0 mIU/L, free T4 in the upper half of the reference range Detects the thyroid suppression seen in animal work TSH is thyroid-stimulating hormone and T4 is thyroxine, the main thyroid hormone. Conventional labs accept TSH up to 4.5 mIU/L. A morning sample is preferred; most relevant for anyone on thyroid replacement
hs-CRP Below 0.5 mg/L Tracks the inflammatory endpoint the plant targets hs-CRP is high-sensitivity C-reactive protein, a general marker of inflammation. Conventional cardiac cut-offs use 1–3 mg/L. Invalid within two weeks of any infection or injury
Sperm concentration and motility Above 40 million/mL, above 45% progressive motility Monitors the best-replicated harm World Health Organization lower reference limits are 15 million/mL and 30%; the higher targets give a warning margin. Requires 2–7 days abstinence before collection

Qualitative markers worth tracking alongside the laboratory panel:

  • Joint comfort and morning stiffness duration, since the anti-inflammatory evidence is joint- and skin-directed
  • Skin appearance and irritation, both as a potential benefit and as the earliest sign of an allergic reaction
  • Bowel habit, specifically any shift toward constipation, which is the expected direction from tannin-rich preparations
  • Energy levels and exercise tolerance, which would fall early if haemoglobin were declining
  • Libido and morning erections in men, as a subjective signal that complements the semen analysis
  • Absence of new symptoms — mouth or throat irritation, dark urine, or right-upper-abdominal discomfort — each of which is a stop-and-test signal

Emerging Research

  • No registered clinical trial exists: Searches of ClinicalTrials.gov on 17 August 2026 for Butea monosperma, Butea frondosa and butein returned no interventional or observational study. No NCT ID can be cited because none has been assigned, so there is no ongoing trial to follow.

  • Bone: from fraction to single molecule: The standardised bark fraction work by Pandey et al., 2010 pointed toward cladrin and medicarpin as individual drug candidates. A first-in-human dose-finding study of either would strengthen the bone case decisively, or end it.

  • Bone: beyond newborn-rat bone cells: Sundar et al., 2024 reported that bark extract activates Wnt/β-catenin signalling (a core bone-building pathway) in rat adipose-derived mesenchymal stem cells. Replication in human cells is the next step, and would strengthen the case.

  • Aging biology needs a mammal: Kim et al., 2024 showed butein lifespan effects in nematodes with a fertility trade-off. A mammalian lifespan study would settle whether this transfers, and the fertility finding means it could equally weaken the case.

  • The sirtuin premise is contested: Butein entered aging research through the 2003 sirtuin-activator screen by Howitz et al. The fluorogenic assay behind that screen has since been argued to generate artefacts. Resolving this would either restore or remove butein’s main longevity rationale.

  • Reproductive toxicology needs dose-response: Parween et al., 2021 established the harm at 500 mg/kg/day over 180 days but tested only two doses. A proper dose-response study would establish whether human-realistic intakes reach the threshold at all.

  • Computational leads awaiting wet-lab work: Mondal et al., 2025 used network pharmacology and docking to propose multi-target action of bark extract in ulcerative colitis. Docking predictions fail often, so this could resolve in either direction once tested experimentally.

  • Analytical standardisation: Negi et al., 2023 established marker compounds and quantitative methods for flower preparations. Reliable quantification is the precondition for any reproducible dosing study, and its absence has held the field back more than any single biological question.

Conclusion

Butea monosperma is a tree of the Indian subcontinent whose flowers, bark, seeds and gum have been used in traditional Indian medicine for centuries and which now attracts attention for two quite separate reasons: an orange pigment in its flowers that damps inflammatory signalling and shows stress-resistance and lifespan effects in simple laboratory organisms, and a distinct group of bark molecules that stimulate bone-building cells without acting like estrogen.

The evidence base is thin in a specific way. It is broad, consistent in direction, and almost entirely animal and cell-culture work. A single small placebo-controlled human trial exists, of a two-component traditional preparation for urinary stones. Nothing else has been tested in people, and no pooled analysis of the research on any claimed effect has been published. Much of the bone research comes from one government institute that has pursued these molecules as drug candidates, and the skin research from a cosmetics manufacturer’s laboratory — both parties with a stake in a favourable finding. In India the same ministry that regulates these products also promotes the sector making them.

Against that sits a real and repeatedly observed harm: suppression of male reproductive function in animals, reversible on stopping, alongside organ and blood toxicity from seed preparations. The honest summary is that the promising signals are early, the main harm is better established than any of the benefits, and the gap between the two is unresolved.

Top - Benefits - Risks - Protocol